Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ATR-101 for the Treatment of Cushing's Syndrome

Trial Profile

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ATR-101 for the Treatment of Cushing's Syndrome

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Jan 2019

At a glance

  • Drugs Nevanimibe (Primary)
  • Indications Cushing syndrome
  • Focus Therapeutic Use
  • Sponsors Millendo Therapeutics
  • Most Recent Events

    • 23 Oct 2018 Planned End Date changed from 1 Nov 2018 to 1 Nov 2020.
    • 23 Oct 2018 Planned primary completion date changed from 1 Nov 2018 to 1 Nov 2020.
    • 04 Apr 2017 Trial design presented at The 99th Annual Meeting of the Endocrine Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top